The Newsroom

Investigations  /  02.17.2021

Investigation of Bluebird Bio, Inc.

You Have Legal Options

Bluebird Bio, Inc. (BLUE) Misled Shareholders About the Viability of LentiGlobin     

According to the complaint, in May 2020, bluebird announced it expected to submit a U.S. Biologistcs Licensing Application to the U.S. Food and Drug Administration (FDA) for LentiGlobin for SCD in the second half of 2021.  However, the data supporting bluebird’s submission was insufficient to demonstrate drug product comparability and the Company downplayed the impact of disruptions related to the COVID-19 pandemic on its submission schedule, particularly with respect to manufacturing.

On November 4, 2020, bluebird disclosed that it would no longer apply for FDA approval of its LentiGlobin product as a treatment for SCD in the second half of 2021 as expected.  Citing feedback from the FDA requiring the Company to provide additional data “to demonstrate drug product comparability” for LentiGlobin for SCD, “alongside COVID-19 related shifts and contract manufacturing organizations COVID-19 impacts,” bluebird adjusted its submission timing to late 2022. On this news, bluebird’s stock fell $9.72 per share, or over 16%, to close at $48.83 per share on November 5, 2020.

If you purchased shares of Bluebird Bio, Inc. (BLUE) between May 11, 2020 and November 4, 2020, you have until April 13, 2021, to ask the court to appoint you lead plaintiff for the class.

  • If you would like more information about your rights and potential remedies please send us a message. 

  • Please Note: Neither the submission to nor the receipt of information by Robbins LLP or one of its attorneys through this website constitutes an agreement by our firm to represent the individual and does not create an attorney-client relationship. Please do not send confidential or sensitive information through this website. This information should be communicated through a direct contact with an individual at the firm.


How can we help you?

CONTACT US TODAY | 1 800 350 6003 or [email protected]

Tell us your concerns